EU agency moves forward meeting on Moderna COVID-19 vaccine

Health Resource Center
This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

AMSTERDAM (AP) — The European Union’s medicines agency announced Thursday that it has moved forward a meeting to consider authorizing a coronavirus vaccine made by Moderna for use in the 27-nation bloc.

The Amsterdam-based agency, which is meeting Monday to consider authorizing a vaccine made by Pfizer Inc. and German company BioNTech for use in the EU, had scheduled a meeting to discuss the Moderna vaccine on Jan. 12, but that has now been brought forward to Jan. 6.

The decision came after Moderna sent that last package of data on the vaccine needed for the agency to assess it for the EU market, the EMA said.

“We have constantly revised our planning to further streamline all the procedural aspects that need to be in place for a robust scientific assessment that leads to a marketing authorization in all EU countries,” EMA Executive Director Emer Cooke said. “The number of infections is increasing across Europe and we are aware of the huge responsibility we have to get a vaccine to the market as quickly as is feasible, whilst maintaining the robustness of our scientific review.”

The EMA’s approval is valid in all 27 EU countries and once it is granted, countries can start receiving vaccines for immunization campaigns.


Follow AP’s pandemic coverage at:

Copyright 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Don't Miss